Cancer News and Research

Latest Cancer News and Research

Prolonged exposure to formaldehyde linked with increased risk of myeloid leukemia

Long durations of exposure to formaldehyde used for embalming in the funeral industry were associated with an increased risk of death from myeloid leukemia, according to a new study published online November 20 in the Journal of the National Cancer Institute.

21 Nov 2009

Zoladex consumers entitled to treble damages, Court rules

The United States Court of Appeals for the First Circuit upheld an earlier District Court ruling yesterday, approving a settlement in the long-running Average Wholesale Price (AWP) pharmaceutical litigation against AstraZeneca Pharmaceuticals ( AZN).

21 Nov 2009

PhRMA reaffirms its commitment to support the health reform

POLITICO recently published an editorial by Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson. In the editorial, Johnson makes the case for health reform and reaffirm's PhRMA's commitment to supporting this historic effort.

21 Nov 2009

"Hotline" report on finasteride for prevention of prostate cancer

In response to a recent New York Times article that questions why currently available medications designed to treat and prevent some cancers are being ignored, ECRI Institute, an independent nonprofit organization, is offering a roadmap to the evidence on Finasteride for Prevention of Prostate Cancer for free download.

20 Nov 2009

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

The debate on how to select patients who will respond best to costly drug treatments for aggressive breast cancer now favors fluorescence in situ hybridization (FISH) to measure the HER-2 receptor found in human breast tumors, according to a leading pathologist presenting at the Association for Molecular Pathology annual meeting.

20 Nov 2009

Guidelines on cancer screenings spark debate

New guidelines on mammograms and pap smears set off a fierce debate.

20 Nov 2009

Study reveals effectiveness of radiation therapy in achieving local control and palliation in patients with PNTs

Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

20 Nov 2009

A selection of today's opinions and editorials

These bills will provide a bedrock sense of security and stability for Americans who have health insurance, and quality, affordable options for Americans without it (Peter R. Orszag, 11/20).

20 Nov 2009

CVS/pharmacy kicks off its fundraiser for St. Jude Children's Research Hospital's annual campaign

CVS/pharmacy kicks off its annual in store fundraiser for the sixth year to support the St. Jude Children's Research Hospital Thanks and Giving campaign, beginning this Sunday and running through December 12. CVS/pharmacy store colleagues will encourage customers to add $1 to their purchase at the register to support the lifesaving research of St. Jude, one of the world's premier centers for the research and treatment of pediatric cancer and other catastrophic childhood diseases.

20 Nov 2009

Antigenics to withdraw its MAA for Oncophage following CHMP’s negative opinion

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) as a treatment in earlier-stage, localized renal cell carcinoma (kidney cancer).

20 Nov 2009

FDA acknowledges Dendreon's amended BLA for PROVENGE as a complete response

Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

20 Nov 2009

Boston Scientific's WallFlex Fully Covered Esophageal Stent receives FDA clearance and CE Mark approval

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex® Fully Covered Esophageal Stent for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable esophageal cancer.

20 Nov 2009

Health policy research roundup

Urban Institute: Progress Enrolling Children in Medicaid/CHIP: Who Is Left And What Are The Prospects For Covering More Children? - This policy brief examines the characteristics of the estimated 5 million uninsured children who are eligible for CHIP/Medicaid in 2007 (64 percent of all uninsured children; 88 percent of all low-income uninsured children), but not enrolled.

20 Nov 2009

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.

20 Nov 2009

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.

20 Nov 2009

Soligenix receives $9.4M NIAID grant to develop technology for advancing rapidly acting vaccines

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has formed a consortium to develop thermostable technology to advance RiVax(TM) and other rapidly acting vaccines. Soligenix received a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to support this work.

20 Nov 2009

Inovio Biomedical announces positive test results of its consensus influenza vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets.

20 Nov 2009

Quit smoking and get Karen Sokolof Javitch's "STAR TRACKS - THE TRIBUTE ALBUM" CD for free

Karen Sokolof Javitch is hoping that her new CD: STAR TRACKS - THE TRIBUTE ALBUM will encourage people to throw away their cigarettes! "It's worth a try," says Javitch, who decided to dedicate her CD to Patrick Swayze, who recently died of pancreatic cancer. "He was a 3-pack-a-day smoker, and never quit, even when he got sick." Her mother also died at age 56 (like Patrick) and she is sure cigarette smoking contributed to her death.

20 Nov 2009

German Research Foundation approves 9.4 million euros funding for University of Freiburg

The authorization committee of the German Research Foundation (DFG) has approved funding for a collaborative research center proposed by the University of Freiburg on the topic „Control of Cell Motility in Morphogenesis, Tumor Invasion, and Metastatic Spread" starting on 1 January 2010. The Freiburg SFB 850 will receive a total of 9.4 million euros in the next four years plus a 20 percent program allowance for indirect costs. In the case of success, the SFB 850 is eligible to receive funding for up to 12 years.

20 Nov 2009

2nd EMUC Meeting to discuss urological cancer

Experts agree that the urological cancer patient will benefit greatly if the delivered treatment is the result of a combined effort. Collaboration of experts from various fields is, therefore, necessary to take cancer-related research and medical practice to the next level.

20 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Prolonged exposure to formaldehyde linked with increased risk of myeloid leukemia

Zoladex consumers entitled to treble damages, Court rules

PhRMA reaffirms its commitment to support the health reform

"Hotline" report on finasteride for prevention of prostate cancer

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

Guidelines on cancer screenings spark debate

Study reveals effectiveness of radiation therapy in achieving local control and palliation in patients with PNTs

A selection of today's opinions and editorials

CVS/pharmacy kicks off its fundraiser for St. Jude Children's Research Hospital's annual campaign

Antigenics to withdraw its MAA for Oncophage following CHMP’s negative opinion

FDA acknowledges Dendreon's amended BLA for PROVENGE as a complete response

Boston Scientific's WallFlex Fully Covered Esophageal Stent receives FDA clearance and CE Mark approval

Health policy research roundup

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Soligenix receives $9.4M NIAID grant to develop technology for advancing rapidly acting vaccines

Inovio Biomedical announces positive test results of its consensus influenza vaccines

Quit smoking and get Karen Sokolof Javitch's "STAR TRACKS - THE TRIBUTE ALBUM" CD for free

German Research Foundation approves 9.4 million euros funding for University of Freiburg

2nd EMUC Meeting to discuss urological cancer

Cancer Research - Second Edition eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in